SCHEMBL5790074

SCHEMBL5790074

NCc1ccc(Sc2ccc(Cl)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.52
CHRNA7 P36544 1/20 0.52
TAAR1 Q96RJ0 2/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
RAB9A P51151 1/20 0.47
MAOA P21397 2/20 0.47
PNMT P11086 1/20 0.45
HRH3 Q9Y5N1 1/20 0.44
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.42
POLB P06746 1/20 0.42
PTGIR P43119 1/20 0.41
SLC6A4 P31645 1/20 0.41
IDO1 P14902 1/20 0.41
AGXT P21549 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL107396 0.85
Bromide SCHEMBL31513717 0.83 MAOB (0.61) MAOBTAAR1PNMTHRH3SLC6A2
Methane SCHEMBL10521618 0.83 MAOB (0.61) MAOBTAAR1PNMTHRH3SLC6A2
Iodide SCHEMBL29120576 0.83 MAOB (0.61) MAOBTAAR1PNMTHRH3SLC6A2
Ammonia Solution, Strong SCHEMBL9177329 0.83 MAOB (0.61) MAOBTAAR1PNMTHRH3SLC6A2
Hydrochloric Acid SCHEMBL927415 0.83 MAOB (0.65) MAOBTAAR1PNMTHRH3SLC6A2
SCHEMBL9476350 0.80 MAOA (0.64) MAOBCHRNA7MEN1KMT2ANPC1
SCHEMBL9475224 0.80 MAOA (0.64) MAOBCHRNA7MEN1KMT2ANPC1
SCHEMBL481976 0.80 MAOA (0.64) MAOBCHRNA7MEN1KMT2ANPC1
SCHEMBL7264028 0.79 MEN1 (0.55) MAOBCHRNA7TAAR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106183520-A Original edition of lithographic printing plate and printing process thereof 富士胶片株式会社 2016-12-07 CN disclosed
US-7078401-B2 Thiophenylaminoimidazolines as IP antagonists ROCHE PALO ALTO LLC (US) 2006-07-18 US disclosed
EP-1656350-A2 THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP disclosed
US-20050020648-A1 Thiophenylaminoimidazolines as IP antagonists ROCHE PALO ALTO LLC 2005-01-27 US disclosed
WO-2005005394-A2 THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020648-A1 Thiophenylaminoimidazolines as IP antagonists TBXA2R, MRGPRX2, MRGPRX1 MAOB 2554/4885CHRNA7 278/4885TAAR1 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.